喘息および慢性閉塞性肺疾患（COPD）のための創薬動向
Asthma and COPD Drug Discoveries: What the future holds
概要（日本語）
喘息および慢性閉塞性肺疾患市場は現在200億米ドル規模であり、2005年には上位12の医薬品が総売上157億米ドルを達成しました。
医療機器、医薬品などに関する情報提供で世界的に高い評価を得ております英国の調査会社Espicom Business Intelligenceは、喘息および慢性閉塞性肺疾患のための創薬動向についてまとめた報告書"Asthma and COPD Drug Discoveries: What the future holds"を発行いたしました。
当報告書は、喘息および慢性閉塞性肺疾患の概要、診断と治療法、市場リーダー企業動向、および各分野の創薬動向について詳細に調査分析し、概略下記の構成で取り上げております。
原文
The global asthma and COPD market is currently worth around US$20 billion. The top twelve pharmaceutical products by value had combined global sales of US$15.7 billion in 2005. Six brands had sales in excess of US$1 billion. Combined sales of the top ten products were 21.1% higher than in 2004.
A number of older therapies, for asthma in particular, are widely available generically and there is fierce competition in the market. The asthma market accounts for the majority of the total and is valued at around US$15 billion. The COPD market is currently valued at US$4 - US$5 billion and is set to double in the next five years.
Future market growth will be driven by increasing disease awareness, an increasing patient pool, both in the paediatric asthma sector and the ageing population susceptible to COPD, and the launch of newer, more expensive therapies targeting areas of high unmet clinical need. These will be offset to some extent by the launch of new generics and the sales erosion of monotherapies by combination products.
利用規約
